HIVE Digital Technologies Surpasses 13 EH/s as Scalable Growth and Revenue Expansion Accelerate in Paraguay and Reaches $300 Million ARR This news release constitutes a "designated news release" for the purposes of the Company's amended and restated prospectus supplement dated May 14, 2025, to its short form base shelf prospectus dated September 11, 2024. July 24, 2025 1:00 AM EDT | Source: HIVE Digital Technologies Ltd. San Antonio, Texas--(Newsfile Corp. - July 24, 2025) - HIVE Digital Technologies Ltd. ( ...

公司业绩展望 - 2025年集团销售额预计以固定汇率计算实现中个位数增长 [1] - 核心每股收益目标为高个位数增长 [1] - 计划进一步增加瑞士法郎股息 [1] 2025年上半年财务表现 - 集团销售额达30944百万瑞士法郎 同比增长7%(CER) [2] - 制药部门销售额23985百万瑞士法郎 同比增长10%(CER) [2] - 诊断部门销售额6959百万瑞士法郎 同比持平(CER) [2] - 核心营业利润12010百万瑞士法郎 同比增长11%(CER) [2] - 稀释后核心每股收益11.08瑞士法郎 同比增长12%(CER) [2] - IFRS净利润7832百万瑞士法郎 同比增长23%(CER) [2] 主要产品表现 - 五大增长驱动产品(Phesgo/Xolair/Hemlibra/Vabysmo/Ocrevus)总销售额106亿瑞士法郎 同比增长17亿瑞士法郎(CER) [7] - Ocrevus(多发性硬化症)销售额35亿瑞士法郎 同比增长8% [16] - Hemlibra(血友病A)销售额24亿瑞士法郎 同比增长17% [16] - Vabysmo(眼部疾病)销售额21亿瑞士法郎 同比增长18% [16] 区域销售表现 - 美国市场销售额增长10% 主要受益于Xolair/Hemlibra/Ocrevus/Vabysmo/Phesgo [9] - 欧洲市场增长5% 主要驱动产品为Vabysmo/Ocrevus/Polivy/Phesgo [10] - 日本市场增长5% 主要驱动产品为Phesgo/Vabysmo/PiaSky [11] - 国际市场增长14% 中国区增长9% [12] 研发里程碑 - NXT007(血友病A)在最高剂量组实现零治疗出血 [27] - Lunsumio与Polivy组合疗法使淋巴瘤患者无进展生存期延长至11.5个月 [27] - Prasinezumab(帕金森病)进入III期临床开发 [27] - Tecentriq联合疗法使小细胞肺癌患者疾病进展风险降低46% [27] - Itovebi(乳腺癌)使PIK3CA突变患者死亡风险降低30%以上 [29] 监管审批进展 - Susvimo获FDA批准用于糖尿病视网膜病变 [15] - Itovebi获欧盟批准用于PIK3CA突变晚期乳腺癌 [15] - Evrysdi片剂获欧盟批准作为首个SMA口服治疗 [15] - CHMP推荐Phesgo标签更新允许家庭给药 [23] 诊断部门发展 - 与Broad Clinical Labs合作推进SBX测序技术应用 [18] - VENTANA MET(SP44)RxDx Assay获FDA批准作为首个伴随诊断 [19] - 推出Elecsys PRO-C3测试提高肝纤维化评估精度 [19] - 获得首个AI驱动伴随诊断突破性设备认定 [23]

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 31, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 2025 financial results and provide a second quarter business update. July 24, 2025 A webcast of the live call may be accessed on the Investors section of the argenx website at argen ...

Nokia Corporation Half year financial report24 July 2025 at 08:00 EEST Nokia Corporation Report for Q2 and Half Year 2025Solid performance offset by currency impact Q2 comparable net sales declined 1% y-o-y on a constant currency and portfolio basis (2% reported) due to a 13% decline in Mobile Networks which had benefited from accelerated revenue recognition in the prior year. Network Infrastructure grew 8% while Cloud and Network Services grew 14%. Nokia Technologies grew 3%.Comparable gross margin in Q2 w ...

   VANCOUVER, British Columbia – TheNewswire - July 23, 2025 – Carrier Connect Data Solutions Inc. (TSX.V:CCDS; OTCQB:CCDSF; WKN: A40XB1) (the “Company” or “Carrier”) reports that it has completed its previously announced acquisition of all outstanding share capital of Nexion W1 DC Pty Ltd. (the “Target”) from Nexion Group Ltd. (the “Vendor”) pursuant to the terms of a share purchase agreement dated July 10, 2025 (the “Agreement”).  The Target operates a 2 Megawatt Tier II/III data center in Perth, Australi ...

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or a ...

GE Healthcare业务概况 - GE Healthcare从通用电气分拆后成为独立上市公司 2023年初完成分拆 目前年收入达196亿美元 服务覆盖160个国家超10亿患者[5] - 业务模式采用"D3战略"：智能设备(Smart Devices)、智能药物(Smart Drugs)和数字解决方案(Digital Solutions)相结合 聚焦癌症和心血管疾病等特定疾病领域[6] - 影像部门年收入90亿美元 产品线涵盖X光、CT、MRI和分子影像等 其中分子影像(如PET CT)是未来增长重点[3][9][10] 技术创新与AI应用 - 公司拥有85款FDA批准的AI医疗设备 AI技术使MRI重建时间缩短70% 心脏检查时间减少83% 已服务超3000万患者[13][14] - 研发重点包括：CT光子计数架构、分子影像新同位素应用 以及跨设备数据整合的AI解决方案[11][20] - AI应用场景：消除影像伪影提升诊断信心 优化检查流程提高患者吞吐量 并辅助医生生成综合诊断报告[14][18][20] 行业竞争与生态系统 - 通过收购Caption Health(超声)和MIM(分子影像软件)等AI公司强化技术布局 同时与大型医疗系统共建开放生态系统[19] - 竞争优势体现在：FDA获批AI设备数量领先 以及从单设备优化到全诊疗流程整合的解决方案能力[19][20] - 结合精益管理(Lean)与AI技术 同步提升内部研发效率和临床服务能力[17] 产品演进与市场机会 - 影像技术历经四代发展：从基础X光到分子影像 当前PET CT/MR在癌症诊疗中展现最大增长潜力[9][10] - 成熟市场MRI普及度高 但分子影像的临床适应症仍在扩展 新兴市场对高端影像设备存在显著未满足需求[10] - 服务收入构成重要板块 包括设备维护和AI算法更新等持续服务 形成长期客户粘性[8]

Investors clamouring for a budget Tesla just got more intel about it. The EV giant's CEO, Elon Musk, said on Wednesday that Tesla's long-awaited affordable model will resemble the Model Y.Musk was speaking to investors in Tesla's latest earnings call when an analyst asked for more details about the budget-friendly EV Musk has long been touting. "It's just a Model Y. Let the cat out of the bag there. Dancing cat that can talk and sing and dance," Musk said. "That's the cool part."Musk did not give further ...

It has been a while since I initiated coverage on Lockheed Martin Corporation (NYSE: LMT ). Looking back, I put a buy rating basically at the stock's peak, and underperformance has since followed. Declines since that*Please consider following my new X/Twitter account for reaction to market developments and news.* I'm a full-time investor with a strong focus on the tech sector. I graduated with a Bachelor of Commerce Degree with Distinction, major in Finance. I'm also a proud lifetime member of the Beta Gamm ...

Analyst's Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or a ...